Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(3):222-225
DOI: 10.5428/pcar20190316
Clinical practice of pharmacists involved in individualized medication of vancomycin in the patients with augmented renal clearance
1. XUE Shengmin1(1.Department of Pharmacy,Suzhou Hospital Affiliated to Nanjing Medical University,Jiangsu Suzhou 215002,China 531231223@qq.com)
2. TANG Lian1(1.Department of Pharmacy,Suzhou Hospital Affiliated to Nanjing Medical University,Jiangsu Suzhou 215002,China )
3. FANG Jie2(2.Department of Pharmacy,Ruijin Hospital Affiliated to School of Medicine,Shanghai Jiaotong University,Shanghai 200025,China )
4. LU Haodi1(1.Department of Pharmacy,Suzhou Hospital Affiliated to Nanjing Medical University,Jiangsu Suzhou 215002,China )
5. SHANG Erning1(1.Department of Pharmacy,Suzhou Hospital Affiliated to Nanjing Medical University,Jiangsu Suzhou 215002,China )
6. XUE Sudong1(1.Department of Pharmacy,Suzhou Hospital Affiliated to Nanjing Medical University,Jiangsu Suzhou 215002,China sz-xue sudong@163.com)
ABSTRACT  Objective: To explore the role of occupational pharmacists involved in anti-infection individualized medication of vancomycin in the patients with augmented renal clearance based on “accurate pharmacy”.Methods: Clinical pharmacists were involved in the dosage adjustment of individualized medication of vancomycin in 3 patients with augmented renal clearance.Based on “accurate pharmacy” and with the assistance of the classical pharmacokinetic software (Vancomycin Calculator) combined with JPKD-vancomycin population pharmacokinetics software, clinical pharmacists helped physicians to perfect treatment profiles, monitor adverse drug reactions(ADRs) and guide the adjustment of treatment profiles.Results: Through prediction of trough concentration of vancomycin, clinical pharmacists helped physicians to adjust treatment profiles, maintain stable serum drug concentration within the target range, ensure therapeutic effects, at the same time, intensify the monitoring of possible ADRs.Conclusion: By the way of population pharmacokinetics, clinical pharmacist involvement in individualized medication of vancomycin could increase the rates of reaching the standards of vancomycin trough concentration and clinical efficacy, and render pharmaceutical service in the rational use of vancomycin clinically.
Welcome to PCAR! You are the number 182 reader of this article!
Please cite this article as:
XUE Shengmin1,TANG Lian1,FANG Jie2,LU Haodi1,SHANG Erning1,XUE Sudong1,. Clinical practice of pharmacists involved in individualized medication of vancomycin in the patients with augmented renal clearance[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(3): 222-225.
References:
1. Udy A A,Varghese J M,Altukroni M,et al.Subtherapeutic initial β-lactam concentrations in select critically ill patients:association between augmented renal clearance and low trough drug concentrations[J].Chest,2012,142(1):30-39.
2. Campassi M L,Gonzalez M C,Masevicius F D,et al.Augmented renal clearance in critically ill patients:incidence,associated factors and effects on vancomycin treatment[J].Rev Bras Ter Intensiva,2014,26(1):13-20.
3. HE Juan,MAO Enqiang,JING Feng,et al.PK/PD of vancomycin in patients with severe acute pancreatitis combined with augmented renal clearance[J].Chin Crit Care Med,2017,29(9):810-814.In Chinese with English abstract.
4. FANG Jie,LIU Liyan,HUANG Jie,et al.Study on the optimization of dosage regimen of vancomycin[J].Pharm Care Res,2017,17(3):179-182.In Chinese with English abstract.
5. Ishii H,Hirai K,Sugiyama K,et al.Validation of a nomogram for achieving target trough concentration of vancomycin:accuracy in patients with augmented renal function[J].Ther Drug Monit,2018,40(6):693-698.
6. Bilbao-Meseguer I,Rodríguez-Gascón A,Barrasa H,et al.Augmented renal clearance in critically ill patients:a systematic review[J].Clin Pharmacokinet,2018,57(9):1107-1121.
7. Kawano Y,Morimoto S,Izutani Y,et al.Augmented renal clearance in Japanese intensive care unit patients:a prospective study[J].J Intensive Care,2016,4:62.
8. TANG Lian,LU Haodi,XUE Shengmin,et al.The influencing factors of pharmacokinetics of vancomycin and its trough concentration in patients with augmented renal clearance[J].Int Med Health Guid News,2018,24(5):621-628.In Chinese with English full text.
9. Lodise T P,Lomaestro B,Graves J,et al.Larger vancomycin doses (at least four grams per day) are associted with an increased incidence of nephrotoxicity[J].Antimicrob Agents Chemother,2008,52(4):1330-1336.
10. Nelson N R,Morbitzer K A,Jordan J D,et al.The impact of capping creatinine clearance on achieving therapeutic vancomycin concentrations in neurocritically ill patients with traumatic brain injury[J].Neurocrit Care,2019,30(1):126-131.
11. Expert Group on Clinical Dosage of Vancomycin.Chinese expert consensus on the clinical dosage of vancomycin[J].Chin J Infect Dis,2012,30(11):641-646.In Chinese.
12. De Waele J J,Dumoulin A,Janssen A,et al.Epidemiology of augmented renal clearance in mixed ICU patients[J].Minerva Anestesiol,2015,81(10):1079-1085.
13. LU Haodi,TANG Lian,XUE Shengmin,et al.Clinical verification of vancomycin population pharmacokinetics in patients with augmented renal clearance[J].Chin Crit Care Med,2018,30(5):444-448.In Chinese with English abstract.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口